Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Tibolone and risk of gynecological hormone sensitive cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Does HPV status influence survival after vulvar cancer?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-term risk of cervical cancer following conization of cervical intraepithelial neoplasia grade 3-A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Contemporary Hormonal Contraception and the Risk of Breast Cancer

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Parental Rheumatoid Arthritis and Autism Spectrum Disorders in Offspring: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association of Hormonal Contraception With Suicide Attempts and Suicides

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Risk of ovarian cancer with hormone therapy is associated with use of both unopposed estrogen therapy and combined estrogen-progestin therapy, whereas for endometrial cancer addition of continuous progestin decreases the estrogen induced increased risk. Less is known about risk with use of tibolone; a synthetic steroid with estrogenic, progestagenic, and androgenic properties. We assessed these associations in a prospective cohort study, including all Danish women 50-79 years of age and followed 1995-2009. National Danish Registers captured individually updated exposure information, cancer cases including histology and confounding factors. Poisson regression analyses provided multiple adjusted incidence rate ratio's (IRR). More than 900,000 women were followed for 9.8 years on average; 4,513 were diagnosed with ovarian cancer and 6,202 with endometrial cancer. Compared to women never on postmenopausal hormone therapy, current users of tibolone had an increased IRR for ovarian cancer (1.42(95% confidence interval [CI], 1.01-2.00) and serous ovarian tumors (2.21(95%CI 1.48-3.32)). The risk increased with duration of use, particularly for serous ovarian tumors. Compared to never users, the IRR of endometrial cancer was 3.56(95%CI 2.94-4.32) among current users of tibolone and 3.80(95%CI 3.08-4.69) of Type 1 endometrial cancer. The steepest risk increase with duration of use was for Type I tumors. In conclusion, tibolone is associated with increased risk for ovarian and endometrial cancer overall; and particular the risk of serous ovarian tumors and Type 1 endometrial cancer. Because the associations are stronger with increasing durations of use - and for hormone sensitive tumors -the results seem indicative of causality. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalInternational Journal of Cancer
Volume142
Issue number12
Pages (from-to)2435-2440
ISSN0020-7136
DOIs
Publication statusPublished - 19 Jan 2018

    Research areas

  • Journal Article

ID: 52615075